Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Narcolepsy Therapeutics Market 

5.1. COVID-19 Landscape: Narcolepsy Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Narcolepsy Therapeutics Market, By Treatment

8.1. Narcolepsy Therapeutics Market, by Treatment, 2023-2032

8.1.1. Narcolepsy With Cataplexy

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Narcolepsy Without Cataplexy

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Secondary Narcolepsy

8.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Narcolepsy Therapeutics Market, By Product

9.1. Narcolepsy Therapeutics Market, by Product, 2023-2032

9.1.1. Central Nervous System Stimulants

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Sodium Oxybate

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Selective Serotonin Reuptake Inhibitor

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Tricyclic Antidepressants

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Narcolepsy Therapeutics Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.1.2. Market Revenue and Forecast, by Product (2020-2032)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.1.3.2. Market Revenue and Forecast, by Product (2020-2032)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.1.4.2. Market Revenue and Forecast, by Product (2020-2032)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.2.2. Market Revenue and Forecast, by Product (2020-2032)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.2.3.2. Market Revenue and Forecast, by Product (2020-2032)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.2.4.2. Market Revenue and Forecast, by Product (2020-2032)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.2.5.2. Market Revenue and Forecast, by Product (2020-2032)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.2.6.2. Market Revenue and Forecast, by Product (2020-2032)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.3.2. Market Revenue and Forecast, by Product (2020-2032)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.3.3.2. Market Revenue and Forecast, by Product (2020-2032)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.3.4.2. Market Revenue and Forecast, by Product (2020-2032)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.3.5.2. Market Revenue and Forecast, by Product (2020-2032)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.3.6.2. Market Revenue and Forecast, by Product (2020-2032)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.4.2. Market Revenue and Forecast, by Product (2020-2032)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.4.3.2. Market Revenue and Forecast, by Product (2020-2032)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.4.4.2. Market Revenue and Forecast, by Product (2020-2032)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.4.5.2. Market Revenue and Forecast, by Product (2020-2032)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.4.6.2. Market Revenue and Forecast, by Product (2020-2032)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.5.2. Market Revenue and Forecast, by Product (2020-2032)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.5.3.2. Market Revenue and Forecast, by Product (2020-2032)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Treatment (2020-2032)

10.5.4.2. Market Revenue and Forecast, by Product (2020-2032)

Chapter 11. Company Profiles

11.1. Avadel Pharmaceuticals

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Harmony Biosciences (BIOPROJET)

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Jazz Pharmaceuticals PLC

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Ligand Pharmaceuticals Incorporated

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Novartis AG

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Shionogi Inc.

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Takeda Pharmaceutical Company

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Teva Pharmaceuticals Industries Ltd

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Axsome Therapeutics Inc.

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. XWPharma Ltd.

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms